The Office of Nuclear Physics (NP), Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving applications for research and development that will allow existing technology candidates to demonstrate down-selection criteria for the next generation of neutrinoless double beta decay measurements.
The Office of Nuclear Physics (NP), Office of Science (SC), U.S. Department of Energy (DOE), hereby announces its interest in receiving applications for research and development that will allow existing technology candidates to demonstrate down-selection criteria for the next generation of neutrinoless double beta decay measurements.
The purpose of this Funding Opportunity Announcement (FOA) is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center (Kids First DRC), which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets. Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community.
The purpose of this Funding Opportunity Announcement (FOA) is to establish one or two centers that can rapidly generate high quality whole genome sequence and variant data from a large number of human specimens representing two types of pediatric conditions - childhood cancers and structural birth defects. All sequence data generated under this FOA will be re-processed and harmonized by the Gabriella Miller Kids First Pediatric Data Resource Center (Kids First DRC), which is also charged with building a public-facing, web-based portal that will allow researchers to search, access, aggregate, analyze, and share annotated genomic sequence, variant, and phenotypic datasets. Together these resources will promote comprehensive and cross-cutting research and collaboration within the pediatric research community.
The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
This FOA solicits development of new, more easily accessible tools, reagents, and technologies to facilitate identification, tracking, manipulation, and analysis of glycans with their biological binding partners and determine their functions.
The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
The ability to isolate and analyze single EVs and their cargoes from human biofluids would provide a unique opportunity to understand the cell or tissue from which their respective exRNAs originate (heterogeneity) and, importantly, add significant depth to our understanding of exRNA communication. The overarching goal of this Funding Opportunity Announcement (FOA) is to develop and demonstrate innovative technologies and reagents towards isolating single EVs and to characterize the exRNA cargos associated with specific EV subpopulations based on cell of origin and their intended target cell. Shedding light on the diversity of exRNAs carried by EVs will allow for a better understanding of the precise role of exRNAs as signaling molecules for both physiological and pathophysiological processes, ultimately accelerating development of exRNAs as therapeutics and diagnostics.
This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.
This initiative will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been established in the literature or with preliminary data. Published data can be used to establish the current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely available preprints that have a Digital Object Identifier (DOI) are acceptable.
This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.
This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.
This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimer's disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimer's disease will be deemed nonresponsive to the FOA.
This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimer's disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimer's disease will be deemed nonresponsive to the FOA.
The Coordination Center for the Models of Infectious Disease Agent Study (MIDAS) program will serve as a hub for collaboration, testing and dissemination of research products from the network of MIDAS investigators. The Coordination Center will also serve as the primary repository for MIDAS-related datasets, models and software. The Coordination Center will maintain, promote and maximize utility and use of the shared MIDAS resources. In addition, the Program Director(s)/Principal Investigator(s) of the Coordination Center will proactively develop collaborative activities and educational opportunities intended to enhance the utility of MIDAS resources and to improve the training experiences for members of the MIDAS network and their graduate students and postdoctoral researchers.
Limited funding will also be provided to allow the Coordination Center to conduct impactful research on the evaluation and meta-analysis of existing modeling resources for the study of infectious disease spread and intervention.
This Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the current Building Infrastructure Leading to Diversity (BUILD) awards. BUILD is part of the Enhancing the Diversity of the NIH-Funded Workforce Program, also known as the Diversity Program Consortium (DPC), consists of three integrated initiatives: BUILD, the National Research Mentoring Network (NRMN) and the Coordination and Evaluation Center (CEC). The purpose of the funding is to allow BUILD sites to continue to implement and evaluate the multi-pronged student, faculty, and institutional interventions to enhance diversity in the NIH biomedical research workforce. In preparation for the second phase of the BUILD initiative, the applicants are expected to provide plans to transition into sustainable models for enhancing diversity in the biomedical research fields at their institutions. Applicants are also expected to develop an effective training, mentoring, or research capacity building intervention that will be disseminated to other institutions to increase the national impact of the initiative.
This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
Purpose This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.
This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD. Outcomes of this research may suggest novel opportunities for translational research to allow development of individualized, optimized treatment based on circadian phase and amplitude.
This Limited Competition Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the six current Clinical Centers (CCs) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study of Type 1 Diabetes (T1D) etiology. The TEDDY study involves the rigorous investigation of TEDDY subjects, collecting data and samples, for the identification of infectious agents, dietary factors, or other environmental factors associated with onset of T1D and/or T1D associated autoimmune markers. The six current CCs have been involved in study design and data and biosample acquisition since the inception of the TEDDY consortium. The CCs have recruited participants and followed the subjects over the past 15 years. In addition, the CCs have established effective and proficient collaborations with other components of TEDDY to carry out the studies to meet the objectives of this program. This FOA will support the CCs to allow them to continue to retain, follow clinically, and collect biosamples and data from TEDDY subjects.
The purpose of this Funding Opportunity Announcement (FOA) is to create rodent reporter models for testing in vivo genome editing technologies, and to use these animal models to test genome editing delivery technologies and new genome editors developed under RFA-RM-18-016 and RFA-RM-18-017. The deliverables from the initiative will be a set of animal models (mice and rat), containing one or more reporter genes expressed in all cell types, that will allow facile and quantitative evaluation of genome editing in any cell type of interest. The Testing Centers will use these models to validate new delivery systems and genome editing tools developed by other investigators in the Somatic Cell Genome Editing program. The creation and testing of these rodent models will accelerate the translation of genome editing technologies into treatments for human diseases.
